148 related articles for article (PubMed ID: 37921598)
1. Cisplatin-induced PANDAR-Chemo-EVs contribute to a more aggressive and chemoresistant ovarian cancer phenotype through the SRSF9-SIRT4/SIRT6 axis.
Wang H; Li Y; Wang Y; Shang X; Yan Z; Li S; Bao W
J Gynecol Oncol; 2024 Mar; 35(2):e13. PubMed ID: 37921598
[TBL] [Abstract][Full Text] [Related]
2. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
[TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNA PANDAR promoted radiation and cisplatin-induced DNA damage repair through ATR/CHK1 in NSCLC.
Zhao S; Yu N; Wang H; Wan Z; Diao C; Chen Y; Liu T; Yang Y; Gao F; Bai C; Cao K; Cai J
J Gene Med; 2023 Dec; 25(12):e3565. PubMed ID: 37460393
[TBL] [Abstract][Full Text] [Related]
4. LncRNA WDFY3-AS2 promotes cisplatin resistance and the cancer stem cell in ovarian cancer by regulating hsa-miR-139-5p/SDC4 axis.
Wu Y; Wang T; Xia L; Zhang M
Cancer Cell Int; 2021 May; 21(1):284. PubMed ID: 34051810
[TBL] [Abstract][Full Text] [Related]
5. Long noncoding RNA PANDAR blocks CDKN1A gene transcription by competitive interaction with p53 protein in gastric cancer.
Liu J; Ben Q; Lu E; He X; Yang X; Ma J; Zhang W; Wang Z; Liu T; Zhang J; Wang H
Cell Death Dis; 2018 Feb; 9(2):168. PubMed ID: 29416011
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of circ-PIP5K1A overcomes resistance to cisplatin in ovarian cancer by miR-942-5p/NFIB axis.
Sheng H; Wang X
Anticancer Drugs; 2023 Feb; 34(2):214-226. PubMed ID: 36730637
[TBL] [Abstract][Full Text] [Related]
7. Anlotinib Exerts Inhibitory Effects against Cisplatin-Resistant Ovarian Cancer In Vitro and In Vivo.
Ji Y; Li X; Qi Y; Zhao J; Zhang W; Qu P
Molecules; 2022 Dec; 27(24):. PubMed ID: 36558006
[TBL] [Abstract][Full Text] [Related]
8. Long non-coding RNA CTSLP8 mediates ovarian cancer progression and chemotherapy resistance by modulating cellular glycolysis and regulating c-Myc expression through PKM2.
Li X; Zhang Y; Wang X; Lin F; Cheng X; Wang Z; Wang X
Cell Biol Toxicol; 2022 Dec; 38(6):1027-1045. PubMed ID: 34510316
[TBL] [Abstract][Full Text] [Related]
9. Downregulated expression levels of USP46 promote the resistance of ovarian cancer to cisplatin and are regulated by PUM2.
Xu L; Zhang B; Li W
Mol Med Rep; 2021 Apr; 23(4):. PubMed ID: 33576437
[TBL] [Abstract][Full Text] [Related]
10. Reversal of cisplatin resistance by microRNA-139-5p-independent RNF2 downregulation and MAPK inhibition in ovarian cancer.
Chen Y; Cao XY; Li YN; Qiu YY; Li YN; Li W; Wang H
Am J Physiol Cell Physiol; 2018 Aug; 315(2):C225-C235. PubMed ID: 29719173
[TBL] [Abstract][Full Text] [Related]
11. Hedgehog-Gli2 Signaling Promotes Chemoresistance in Ovarian Cancer Cells by Regulating MDR1.
Wang Q; Wei X; Hu L; Zhuang L; Zhang H; Chen Q
Front Oncol; 2021; 11():794959. PubMed ID: 35059317
[TBL] [Abstract][Full Text] [Related]
12. LDLR promotes autophagy-mediated cisplatin resistance in ovarian cancer associated with the PI3K/AKT/mTOR signaling pathway.
Liu L; Sun YH; An R; Cheng RJ; Li N; Zheng JH
Kaohsiung J Med Sci; 2023 Aug; 39(8):779-788. PubMed ID: 37218642
[TBL] [Abstract][Full Text] [Related]
13. Cancer-associated fibroblast-derived exosomal microRNA-98-5p promotes cisplatin resistance in ovarian cancer by targeting CDKN1A.
Guo H; Ha C; Dong H; Yang Z; Ma Y; Ding Y
Cancer Cell Int; 2019; 19():347. PubMed ID: 31889899
[TBL] [Abstract][Full Text] [Related]
14. Long Non-coding RNA CCAT1 Sponges miR-454 to Promote Chemoresistance of Ovarian Cancer Cells to Cisplatin by Regulation of Surviving.
Wang DY; Li N; Cui YL
Cancer Res Treat; 2020 Jul; 52(3):798-814. PubMed ID: 32124583
[TBL] [Abstract][Full Text] [Related]
15. An increase in long non-coding RNA PANDAR is associated with poor prognosis in clear cell renal cell carcinoma.
Xu Y; Tong Y; Zhu J; Lei Z; Wan L; Zhu X; Ye F; Xie L
BMC Cancer; 2017 May; 17(1):373. PubMed ID: 28545465
[TBL] [Abstract][Full Text] [Related]
16. miR-18a-5p derived from mesenchymal stem cells-extracellular vesicles inhibits ovarian cancer cell proliferation, migration, invasion, and chemotherapy resistance.
Wang X; Jiang L; Liu Q
J Transl Med; 2022 Jun; 20(1):258. PubMed ID: 35672774
[TBL] [Abstract][Full Text] [Related]
17. Toosendanin reduces cisplatin resistance in ovarian cancer through modulating the miR-195/ERK/β-catenin pathway.
Wang G; Li L; Li Y; Zhang LH
Phytomedicine; 2023 Jan; 109():154571. PubMed ID: 36610147
[TBL] [Abstract][Full Text] [Related]
18. SP1-induced lncRNA MCF2L-AS1 promotes cisplatin resistance in ovarian cancer by regulating IGF2BP1/IGF2/MEK/ERK axis.
Zhu Y; Yang L; Wang J; Li Y; Chen Y
J Gynecol Oncol; 2022 Nov; 33(6):e75. PubMed ID: 36245227
[TBL] [Abstract][Full Text] [Related]
19. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer.
Kanlikilicer P; Bayraktar R; Denizli M; Rashed MH; Ivan C; Aslan B; Mitra R; Karagoz K; Bayraktar E; Zhang X; Rodriguez-Aguayo C; El-Arabey AA; Kahraman N; Baydogan S; Ozkayar O; Gatza ML; Ozpolat B; Calin GA; Sood AK; Lopez-Berestein G
EBioMedicine; 2018 Dec; 38():100-112. PubMed ID: 30487062
[TBL] [Abstract][Full Text] [Related]
20. Tumor suppressive microRNA-1 mediated novel apoptosis pathways through direct inhibition of splicing factor serine/arginine-rich 9 (SRSF9/SRp30c) in bladder cancer.
Yoshino H; Enokida H; Chiyomaru T; Tatarano S; Hidaka H; Yamasaki T; Gotannda T; Tachiwada T; Nohata N; Yamane T; Seki N; Nakagawa M
Biochem Biophys Res Commun; 2012 Jan; 417(1):588-93. PubMed ID: 22178073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
